Status of vaccine research and development of vaccines for tuberculosis

Highlights • Tuberculosis is now the leading infectious disease cause of death in the world. • There are more than 10 clinical candidates in various phases of clinical development. • The preclinical portfolio remains small as compare to the problem, and needs novel immunologic approaches. • A correl...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2016-06, Vol.34 (26), p.2911-2914
Main Authors: Evans, Thomas G, Schrager, Lew, Thole, Jelle
Format: Article
Language:English
Subjects:
Adenoviruses
Allergy and Immunology
Animal models
Animals
Antibiotic resistance
Antigens
BCG
BCG Vaccine - therapeutic use
Biomedical Research - trends
Candidates
Clinical trials
Clinical Trials as Topic
Disease transmission
Drug resistance
Funding
Global health
Humans
Immune system
Infections
Influenza
Latency
Mass Vaccination
Mortality
Mycobacterium
Mycobacterium tuberculosis
Portfolio management
Prevention
Proteins
Public health
R&D
Research & development
Teenagers
Tuberculosis
Tuberculosis - prevention & control
Tuberculosis Vaccines - therapeutic use
Vaccine
Vaccines
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c528t-9ab11246123494efeac84838b6951d49d74c811f1ff4d1ec63bcffc75a06d78c3
cites cdi_FETCH-LOGICAL-c528t-9ab11246123494efeac84838b6951d49d74c811f1ff4d1ec63bcffc75a06d78c3
container_end_page 2914
container_issue 26
container_start_page 2911
container_title Vaccine
container_volume 34
creator Evans, Thomas G
Schrager, Lew
Thole, Jelle
description Highlights • Tuberculosis is now the leading infectious disease cause of death in the world. • There are more than 10 clinical candidates in various phases of clinical development. • The preclinical portfolio remains small as compare to the problem, and needs novel immunologic approaches. • A correlate of vaccine-induced protection is not known. • Mass vaccination of adolescents and young adults will likely be the most effective strategy.
doi_str_mv 10.1016/j.vaccine.2016.02.079
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808622935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X16002929</els_id><sourcerecordid>1808622935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-9ab11246123494efeac84838b6951d49d74c811f1ff4d1ec63bcffc75a06d78c3</originalsourceid><addsrcrecordid>eNqFkkGLFDEQhYMo7rj6E5QGL166TSXpTnJRlkVXYcHDKngL6XQFM_Z0xqR7YP-9aWbWlb3sKRR874V6rwh5DbQBCt37bXOwzoUJG1bGhrKGSv2EbEBJXrMW1FOyoawTtQD684y8yHlLKW056OfkjHVacir5hlzdzHZechV9dfKrEma0yf2q7DRUAx5wjPsdTvN_TK58TNW89JjcMsYc8kvyzNsx46vTe05-fP70_fJLff3t6uvlxXXtWqbmWtsegIkOGBdaoEfrlFBc9Z1uYRB6kMIpAA_eiwHQdbx33jvZWtoNUjl-Tt4dffcp_lkwz2YXssNxtBPGJRtQVHWMad4-jkrNNRWCqYK-fYBu45KmsshKtVy2gkKh2iPlUsw5oTf7FHY23RqgZi3FbM0pILOWYigzpZSie3NyX_odDv9Udy0U4OMRwJLcIWAy2QWcHA4hoZvNEMOjX3x44ODGMAVnx994i_l-G5OLwNysl7EeBnSUMl3i-gvZF7P4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1795375401</pqid></control><display><type>article</type><title>Status of vaccine research and development of vaccines for tuberculosis</title><source>ScienceDirect Journals</source><creator>Evans, Thomas G ; Schrager, Lew ; Thole, Jelle</creator><creatorcontrib>Evans, Thomas G ; Schrager, Lew ; Thole, Jelle</creatorcontrib><description>Highlights • Tuberculosis is now the leading infectious disease cause of death in the world. • There are more than 10 clinical candidates in various phases of clinical development. • The preclinical portfolio remains small as compare to the problem, and needs novel immunologic approaches. • A correlate of vaccine-induced protection is not known. • Mass vaccination of adolescents and young adults will likely be the most effective strategy.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2016.02.079</identifier><identifier>PMID: 26973073</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adenoviruses ; Allergy and Immunology ; Animal models ; Animals ; Antibiotic resistance ; Antigens ; BCG ; BCG Vaccine - therapeutic use ; Biomedical Research - trends ; Candidates ; Clinical trials ; Clinical Trials as Topic ; Disease transmission ; Drug resistance ; Funding ; Global health ; Humans ; Immune system ; Infections ; Influenza ; Latency ; Mass Vaccination ; Mortality ; Mycobacterium ; Mycobacterium tuberculosis ; Portfolio management ; Prevention ; Proteins ; Public health ; R&amp;D ; Research &amp; development ; Teenagers ; Tuberculosis ; Tuberculosis - prevention &amp; control ; Tuberculosis Vaccines - therapeutic use ; Vaccine ; Vaccines ; Young adults</subject><ispartof>Vaccine, 2016-06, Vol.34 (26), p.2911-2914</ispartof><rights>World Health Organization</rights><rights>2016 World Health Organization</rights><rights>Copyright © 2016 World Health Organization. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 3, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-9ab11246123494efeac84838b6951d49d74c811f1ff4d1ec63bcffc75a06d78c3</citedby><cites>FETCH-LOGICAL-c528t-9ab11246123494efeac84838b6951d49d74c811f1ff4d1ec63bcffc75a06d78c3</cites><orcidid>0000-0003-0873-1783</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26973073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Evans, Thomas G</creatorcontrib><creatorcontrib>Schrager, Lew</creatorcontrib><creatorcontrib>Thole, Jelle</creatorcontrib><title>Status of vaccine research and development of vaccines for tuberculosis</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Highlights • Tuberculosis is now the leading infectious disease cause of death in the world. • There are more than 10 clinical candidates in various phases of clinical development. • The preclinical portfolio remains small as compare to the problem, and needs novel immunologic approaches. • A correlate of vaccine-induced protection is not known. • Mass vaccination of adolescents and young adults will likely be the most effective strategy.</description><subject>Adenoviruses</subject><subject>Allergy and Immunology</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antibiotic resistance</subject><subject>Antigens</subject><subject>BCG</subject><subject>BCG Vaccine - therapeutic use</subject><subject>Biomedical Research - trends</subject><subject>Candidates</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Disease transmission</subject><subject>Drug resistance</subject><subject>Funding</subject><subject>Global health</subject><subject>Humans</subject><subject>Immune system</subject><subject>Infections</subject><subject>Influenza</subject><subject>Latency</subject><subject>Mass Vaccination</subject><subject>Mortality</subject><subject>Mycobacterium</subject><subject>Mycobacterium tuberculosis</subject><subject>Portfolio management</subject><subject>Prevention</subject><subject>Proteins</subject><subject>Public health</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Teenagers</subject><subject>Tuberculosis</subject><subject>Tuberculosis - prevention &amp; control</subject><subject>Tuberculosis Vaccines - therapeutic use</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Young adults</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkkGLFDEQhYMo7rj6E5QGL166TSXpTnJRlkVXYcHDKngL6XQFM_Z0xqR7YP-9aWbWlb3sKRR874V6rwh5DbQBCt37bXOwzoUJG1bGhrKGSv2EbEBJXrMW1FOyoawTtQD684y8yHlLKW056OfkjHVacir5hlzdzHZechV9dfKrEma0yf2q7DRUAx5wjPsdTvN_TK58TNW89JjcMsYc8kvyzNsx46vTe05-fP70_fJLff3t6uvlxXXtWqbmWtsegIkOGBdaoEfrlFBc9Z1uYRB6kMIpAA_eiwHQdbx33jvZWtoNUjl-Tt4dffcp_lkwz2YXssNxtBPGJRtQVHWMad4-jkrNNRWCqYK-fYBu45KmsshKtVy2gkKh2iPlUsw5oTf7FHY23RqgZi3FbM0pILOWYigzpZSie3NyX_odDv9Udy0U4OMRwJLcIWAy2QWcHA4hoZvNEMOjX3x44ODGMAVnx994i_l-G5OLwNysl7EeBnSUMl3i-gvZF7P4</recordid><startdate>20160603</startdate><enddate>20160603</enddate><creator>Evans, Thomas G</creator><creator>Schrager, Lew</creator><creator>Thole, Jelle</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7U2</scope><orcidid>https://orcid.org/0000-0003-0873-1783</orcidid></search><sort><creationdate>20160603</creationdate><title>Status of vaccine research and development of vaccines for tuberculosis</title><author>Evans, Thomas G ; Schrager, Lew ; Thole, Jelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-9ab11246123494efeac84838b6951d49d74c811f1ff4d1ec63bcffc75a06d78c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adenoviruses</topic><topic>Allergy and Immunology</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antibiotic resistance</topic><topic>Antigens</topic><topic>BCG</topic><topic>BCG Vaccine - therapeutic use</topic><topic>Biomedical Research - trends</topic><topic>Candidates</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Disease transmission</topic><topic>Drug resistance</topic><topic>Funding</topic><topic>Global health</topic><topic>Humans</topic><topic>Immune system</topic><topic>Infections</topic><topic>Influenza</topic><topic>Latency</topic><topic>Mass Vaccination</topic><topic>Mortality</topic><topic>Mycobacterium</topic><topic>Mycobacterium tuberculosis</topic><topic>Portfolio management</topic><topic>Prevention</topic><topic>Proteins</topic><topic>Public health</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Teenagers</topic><topic>Tuberculosis</topic><topic>Tuberculosis - prevention &amp; control</topic><topic>Tuberculosis Vaccines - therapeutic use</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Evans, Thomas G</creatorcontrib><creatorcontrib>Schrager, Lew</creatorcontrib><creatorcontrib>Thole, Jelle</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Evans, Thomas G</au><au>Schrager, Lew</au><au>Thole, Jelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Status of vaccine research and development of vaccines for tuberculosis</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2016-06-03</date><risdate>2016</risdate><volume>34</volume><issue>26</issue><spage>2911</spage><epage>2914</epage><pages>2911-2914</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Highlights • Tuberculosis is now the leading infectious disease cause of death in the world. • There are more than 10 clinical candidates in various phases of clinical development. • The preclinical portfolio remains small as compare to the problem, and needs novel immunologic approaches. • A correlate of vaccine-induced protection is not known. • Mass vaccination of adolescents and young adults will likely be the most effective strategy.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>26973073</pmid><doi>10.1016/j.vaccine.2016.02.079</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-0873-1783</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2016-06, Vol.34 (26), p.2911-2914
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_1808622935
source ScienceDirect Journals
subjects Adenoviruses
Allergy and Immunology
Animal models
Animals
Antibiotic resistance
Antigens
BCG
BCG Vaccine - therapeutic use
Biomedical Research - trends
Candidates
Clinical trials
Clinical Trials as Topic
Disease transmission
Drug resistance
Funding
Global health
Humans
Immune system
Infections
Influenza
Latency
Mass Vaccination
Mortality
Mycobacterium
Mycobacterium tuberculosis
Portfolio management
Prevention
Proteins
Public health
R&D
Research & development
Teenagers
Tuberculosis
Tuberculosis - prevention & control
Tuberculosis Vaccines - therapeutic use
Vaccine
Vaccines
Young adults
title Status of vaccine research and development of vaccines for tuberculosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A06%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Status%20of%20vaccine%20research%20and%20development%20of%20vaccines%20for%20tuberculosis&rft.jtitle=Vaccine&rft.au=Evans,%20Thomas%20G&rft.date=2016-06-03&rft.volume=34&rft.issue=26&rft.spage=2911&rft.epage=2914&rft.pages=2911-2914&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2016.02.079&rft_dat=%3Cproquest_cross%3E1808622935%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c528t-9ab11246123494efeac84838b6951d49d74c811f1ff4d1ec63bcffc75a06d78c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1795375401&rft_id=info:pmid/26973073&rfr_iscdi=true